Hillsdale Investment Management Inc. Purchases 2,107 Shares of Eli Lilly and Company $LLY

Hillsdale Investment Management Inc. boosted its position in shares of Eli Lilly and Company (NYSE:LLY) by 56.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,854 shares of the company’s stock after acquiring an additional 2,107 shares during the period. Hillsdale Investment Management Inc.’s holdings in Eli Lilly and Company were worth $6,291,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in LLY. Maryland Capital Advisors Inc. bought a new stake in shares of Eli Lilly and Company in the 4th quarter valued at approximately $25,000. Miller Global Investments LLC bought a new stake in shares of Eli Lilly and Company in the 4th quarter valued at approximately $33,000. E Fund Management Hong Kong Co. Ltd. grew its stake in shares of Eli Lilly and Company by 342.9% in the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock valued at $32,000 after purchasing an additional 24 shares during the period. Dorato Capital Management bought a new stake in shares of Eli Lilly and Company in the 4th quarter valued at approximately $36,000. Finally, New England Capital Financial Advisors LLC grew its stake in shares of Eli Lilly and Company by 142.9% in the 4th quarter. New England Capital Financial Advisors LLC now owns 34 shares of the company’s stock valued at $37,000 after purchasing an additional 20 shares during the period. 82.53% of the stock is currently owned by institutional investors.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: CVS Caremark is restoring coverage for Zepbound and adding Foundayo to drug plans, meaning all three major PBMs now cover Lilly’s full obesity portfolio. That should expand access for millions of patients and strengthen Lilly’s market share versus Novo Nordisk. Article Title
• Positive Sentiment: Reuters also reported that Mounjaro outperformed other GLP-1 drugs in some type 2 diabetes patients, reinforcing Lilly’s competitive edge in the diabetes and obesity markets. Article Title
• Positive Sentiment: Wall Street is also reacting to Lilly’s broader pipeline momentum, including positive Phase 1b data for Verve-102 and progress in olomorasib, which supports the view that Lilly is more than just a weight-loss story. Article Title
• Positive Sentiment: Lilly announced a major push into vaccines, including the planned acquisition of Curevo Vaccine for $1.5 billion and other vaccine-developer deals, signaling a new long-term growth avenue outside cardiometabolic care. Article Title
• Positive Sentiment: Analyst and media coverage has been upbeat, with commentary highlighting Lilly’s “brilliant management,” record valuation, and strong pipeline, which can help sustain momentum in the stock. Article Title

Eli Lilly and Company Stock Down 1.9%

NYSE LLY opened at $1,105.37 on Friday. The firm has a market cap of $1.04 trillion, a PE ratio of 39.27, a price-to-earnings-growth ratio of 1.21 and a beta of 0.48. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,149.10. The stock’s 50 day simple moving average is $955.92 and its 200 day simple moving average is $1,009.78. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. The business had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.Eli Lilly and Company’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same period in the prior year, the company earned $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, sell-side analysts forecast that Eli Lilly and Company will post 35.8 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $6.92 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is currently 24.58%.

Wall Street Analyst Weigh In

LLY has been the topic of several analyst reports. Wells Fargo & Company upped their price objective on Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $1,285.00 price objective on shares of Eli Lilly and Company in a research note on Friday, March 6th. HSBC lowered Eli Lilly and Company from a “hold” rating to a “reduce” rating and lowered their price objective for the company from $1,070.00 to $850.00 in a research note on Tuesday, March 17th. Leerink Partners set a $1,119.00 price objective on Eli Lilly and Company in a research note on Tuesday. Finally, Freedom Capital upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, February 10th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus target price of $1,227.00.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.